Congenital Bilateral Aplasia of Vas Deferens

Congenital bilateral aplasia of vas deferens, also called congenital bilateral absence of the vas deferens, means a male is born without both vas deferens tubes. These tubes normally carry sperm from the epididymis toward the urethra to become part of semen. In this condition, the testes often make sperm normally, but the sperm cannot travel out in the usual way, so natural fertility is usually not possible. This problem is a form of obstructive male infertility and is often linked to changes in the CFTR gene; some cases are linked to ADGRG2 or other rare genetic causes.

Congenital bilateral aplasia of vas deferens, often called CBAVD, means that a man is born without both vas deferens. These are the two tubes that normally carry sperm from the testes toward the semen. In most men with this condition, the testes still make sperm, male hormones are usually normal, sex drive is usually normal, and erections are usually normal. The main problem is that sperm cannot travel into the semen, so the semen has no sperm or very few sperm. That is why CBAVD is a cause of obstructive male infertility, not usually a problem of weak masculinity or poor sexual performance. CBAVD is strongly linked to changes in the CFTR gene, and some men also have mild cystic-fibrosis-related breathing, sinus, or digestive problems.

An important truth is this: there is no medicine that can grow back the missing vas deferens. Evidence-based care focuses on confirming the diagnosis, checking for related kidney and CFTR problems, offering genetic counseling, and helping the couple have a biological child through sperm retrieval and assisted reproduction such as IVF with ICSI. Because you asked for a drug-heavy article, I need to be exact and honest: medicines may help associated CFTR-related disease or may be used during fertility treatment, but they do not correct the absent tubes themselves.

This condition usually does not reduce sex drive, erection, or male hormone function. Many people feel completely normal in daily life and only learn about the condition during an infertility check. Some men have it as an isolated problem, while others also have mild features related to cystic fibrosis or abnormalities in the kidneys, seminal vesicles, or other parts of the urinary and reproductive tract.

Other names

1. CBAVD means congenital bilateral absence of the vas deferens. This is the short name most doctors use in medical writing.

2. Congenital bilateral absence of the vas deferens is the full standard medical name. “Congenital” means present from birth, and “bilateral” means on both sides.

3. Congenital bilateral aplasia of vas deferens uses the word “aplasia,” which means the structure did not develop normally. It refers to the same condition.

4. Congenital absence of vas deferens is a shorter name. It may refer to one side or both sides, so doctors often add “bilateral” for clarity.

5. CAVD means congenital absence of the vas deferens. This is a broad short form that includes bilateral and unilateral forms.

6. Absent vasa is another older wording. “Vasa” is the plural form of vas deferens.

Types

1. Isolated CBAVD means both vas deferens are absent, but the person does not have the full usual picture of cystic fibrosis. This is a common clinical type.

2. CF-related CBAVD means CBAVD happens as a mild or atypical form of cystic fibrosis caused by CFTR gene changes. Some men may also have mild breathing or digestive problems.

3. CBAVD with urinary tract anomalies means the absent vas deferens is found together with kidney or urinary tract structural problems. This is important because doctors often check the kidneys in these patients.

4. CBAVD with seminal vesicle abnormalities means both vas deferens are absent and the seminal vesicles may also be small, missing, or abnormal. This can help explain very low semen volume and low fructose levels.

Causes

1. CFTR gene mutation is the main known cause. CFTR helps control salt and water movement in cells, and when it does not work well, thick secretions can disturb normal development of the vas deferens before birth.

2. Two CFTR mutations together can cause the condition in an autosomal recessive pattern. This means a disease-causing change is present in both gene copies.

3. One severe and one mild CFTR variant can still lead to CBAVD. This is one reason the condition may appear without classic severe cystic fibrosis.

4. CFTR 5T-related splicing change is a well-known CFTR-related risk mechanism in CBAVD. It can lower normal CFTR function.

5. F508del CFTR mutation is one of the recognized pathogenic CFTR variants reported in CBAVD.

6. R117H CFTR mutation is another reported pathogenic variant linked to CBAVD in some patients.

7. ADGRG2 gene mutation is the second most common known genetic cause. It is especially important in some patients who do not have CFTR mutations.

8. Loss of ADGRG2 protein function can disturb the efferent duct system and is strongly linked with CBAVD development.

9. SLC9A3 deletion or dysfunction has been reported as another possible genetic contributor in some studies.

10. PANK2 mutation has been reported in some CBAVD patients, showing that rare genes may also contribute.

11. Abnormal Wolffian duct development during fetal life can cause the vas deferens not to form properly. The vas deferens develops from this embryologic duct.

12. Thick and sticky fetal secretions from poor CFTR function may block the developing duct and lead to degeneration before birth.

13. Atypical cystic fibrosis biology can present mainly as infertility with CBAVD, even when lung and digestive symptoms are absent or mild.

14. X-linked genetic cause through ADGRG2 is another pathway. Because this gene is on the X chromosome, inheritance can differ from CFTR-related cases.

15. Unknown genetic causes still exist. Medical sources state that some men do not have CFTR mutations and the exact cause remains unknown.

16. Family history of cystic fibrosis or related infertility can point to an inherited cause, especially CFTR-related disease.

17. Associated congenital urinary tract malformations may reflect a shared developmental problem during fetal growth.

18. Associated renal anomalies suggest that in some men, the same early developmental system affecting the vas deferens also affects the kidneys.

19. Associated seminal vesicle maldevelopment can occur with CBAVD and may be part of the same developmental defect.

20. Genetic heterogeneity means CBAVD is not caused by one gene only. Doctors now recognize a group of genetic and developmental pathways behind the same final condition.

Symptoms

1. Infertility is the main symptom. Most men are diagnosed because pregnancy does not happen naturally.

2. No sperm in semen (azoospermia) is a key finding. Sperm may be made in the testes but cannot reach the semen.

3. Very low semen volume is common because the seminal tract is abnormal and semen fluid is reduced.

4. Acidic semen pH can be seen in testing and supports the diagnosis.

5. Low seminal fructose is common and suggests poor seminal vesicle contribution to semen.

6. Small or absent seminal vesicles are often found on imaging and may explain low semen volume.

7. Normal sexual desire is typical, so many men do not notice any sexual problem.

8. Normal erection and sexual performance are usually present. The condition mainly affects sperm transport, not sexual function.

9. Normal puberty and male body development are usual because testosterone production is often normal.

10. No daily symptoms at all is common. Many men feel healthy until infertility testing is done.

11. Mild breathing problems may happen in some CFTR-related cases, especially when CBAVD is part of atypical cystic fibrosis.

12. Mild digestive problems may also occur in some CFTR-related cases, though not in every patient.

13. Features related to kidney anomalies may appear in patients who also have urinary tract malformations, though this is not present in all men.

14. History of failed fertility evaluation despite normal hormones may be a clinical clue. The testes can work, but the sperm pathway is blocked.

15. Emotional stress from infertility is not the cause, but it is a common real-life effect after diagnosis and counseling is often helpful. Fertility and genetic counseling are recommended in major reviews.

Diagnostic tests

1. Physical exam of the scrotum is the first step. The doctor gently feels for the vas deferens, which is usually a firm cord-like tube. In CBAVD, it may not be felt on either side.

2. Manual palpation of both spermatic cords is a focused hand examination. This helps the doctor compare both sides and check whether the vas is truly absent or only hard to feel.

3. Exam of the epididymis and testes checks whether the testes are present and usually normal in size, because sperm production may still be preserved.

4. General genital exam looks for other structural differences that may suggest a broader developmental problem.

5. Semen analysis is a key lab test. It commonly shows azoospermia, meaning no sperm are seen in the semen sample.

6. Measurement of ejaculate volume is part of semen testing. In CBAVD, the volume is often low.

7. Semen pH test helps because semen is often more acidic than usual in this condition.

8. Seminal fructose test is useful because low fructose suggests poor seminal vesicle function or absence.

9. Seminal glycerophosphocholine (GPC) test may also support the diagnosis when levels are low. This is a specialized semen chemistry test.

10. Male hormone blood tests such as FSH, LH, and testosterone help rule out hormone causes of infertility. In CBAVD, these may be normal because the blockage is the main problem.

11. CFTR genetic testing is one of the most important confirmatory tests because CFTR mutations are the main known cause.

12. ADGRG2 genetic testing is useful when CFTR testing is negative, especially in suspected non-CFTR cases.

13. Expanded infertility gene panel may be used in selected patients because not all cases are explained by CFTR alone.

14. Partner CFTR testing is not a test for the man’s anatomy, but it is very important for family planning because it helps estimate the chance of cystic fibrosis in children.

15. Scrotal ultrasound is a simple imaging test. It can help assess the testes, epididymis, and related structures.

16. Transrectal ultrasound helps look at the seminal vesicles and ejaculatory ducts. It is useful when the doctor needs a better view of the internal seminal tract.

17. Renal or abdominal ultrasound is often done to look for kidney abnormalities that can occur with CBAVD.

18. Pelvic MRI gives clearer detail than ultrasound when the diagnosis is uncertain or when doctors need to see remaining duct structures and seminal vesicles more clearly.

19. Testicular sperm retrieval with laboratory examination can show that sperm production is still present, which supports obstructive rather than non-obstructive infertility. This is often used during fertility treatment planning.

20. Electrodiagnostic testing is not a routine test for CBAVD. Unlike nerve or muscle diseases, this condition is usually diagnosed by physical exam, semen tests, imaging, and genetics rather than electrical studies.

Non-Pharmacological Treatments

1. Specialist fertility evaluation. This is the first treatment step because it finds the real cause of infertility and avoids wrong treatment. The doctor checks semen volume, semen pH, fructose, the scrotum, and the vas deferens on exam. The purpose is to prove obstruction and plan the next safe step. The mechanism is simple: once the doctor confirms that sperm production is present but the pathway is missing, treatment can move toward sperm retrieval instead of wasting time on drugs that will not open a tube that never formed.

2. Genetic counseling. This is one of the most important treatments for CBAVD. The purpose is to explain the risk of passing a CFTR-related disorder to a child. The mechanism is decision support: the couple learns whether the male partner carries CFTR variants and whether the female partner should also be tested. This helps them choose IVF, ICSI, embryo testing, or natural family planning with full knowledge, and it lowers the chance of an unexpected cystic-fibrosis-related disease in the child.

3. Partner carrier testing. The female partner should usually be offered carrier screening when CBAVD is linked to CFTR. The purpose is risk reduction for future children. The mechanism is that pregnancy risk becomes much clearer when both partners’ carrier status is known. If both carry important CFTR variants, the couple can discuss embryo testing or prenatal testing before pregnancy happens.

4. Renal ultrasound. Men with vasal agenesis may have kidney or urinary tract abnormalities. The purpose is to look for missing, small, or misplaced kidneys. The mechanism is imaging-based screening, and it matters because a kidney difference may change long-term medical follow-up and surgical planning.

5. CFTR-focused medical review. Some men with isolated CBAVD later show mild airway, sinus, or pancreatic features. The purpose is to look beyond infertility and make sure hidden CFTR-related disease is not missed. The mechanism is early detection, which allows proper referral and long-term care if respiratory or digestive symptoms appear.

6. Semen analysis with low-volume workup. CBAVD often causes very low semen volume, acidic semen, and absent fructose. The purpose is to support the diagnosis. The mechanism is laboratory pattern recognition: this classic semen profile strongly points to distal obstruction or absent ducts rather than hormone failure.

7. Ultrasound of seminal vesicles and reproductive tract. This can show absent or small seminal vesicles and related anatomy. The purpose is anatomical mapping before fertility treatment. The mechanism is visual confirmation of associated tract changes, which helps choose the best sperm retrieval method.

8. Psychological counseling. Infertility can cause shame, fear, and relationship stress. The purpose is emotional support. The mechanism is reduction of anxiety and improvement of decision-making, especially when couples must choose between retrieval, IVF, ICSI, donor sperm, or adoption.

9. Preconception counseling as a couple. This treatment helps the man and his partner understand timing, costs, success chances, and genetic risk before starting procedures. The purpose is better planning. The mechanism is shared decision-making, which reduces rushed or poorly informed treatment.

10. Percutaneous epididymal sperm aspiration, or PESA. This is a common way to collect sperm for ICSI. The purpose is to get sperm directly from the reproductive tract when sperm cannot enter the semen. The mechanism is needle aspiration from the epididymis, bypassing the missing vas deferens.

11. Microsurgical epididymal sperm aspiration, or MESA. This is a more precise microsurgical version of sperm retrieval. The purpose is to obtain usable sperm and sometimes freeze extra sperm for future cycles. The mechanism is direct microsurgical collection from epididymal tubules.

12. Testicular sperm extraction, or TESE. TESE is used when epididymal retrieval is not possible or not successful. The purpose is direct sperm recovery from the testis. The mechanism is small surgical extraction of testicular tissue that may contain sperm.

13. Intracytoplasmic sperm injection, or ICSI. This is one of the main fertility treatments for CBAVD. The purpose is fertilization when only a small number of retrieved sperm are available. The mechanism is injection of one sperm into one egg in the laboratory, which bypasses the missing transport pathway.

14. IVF planning with the female partner. The male diagnosis alone is not enough. The purpose is to assess the woman’s ovarian reserve, age, and reproductive health because those factors strongly influence success. The mechanism is coordinated couple-based fertility care.

15. Cryopreservation of retrieved sperm. Freezing sperm can reduce repeated procedures. The purpose is convenience, lower pain, and future cycle planning. The mechanism is storage of viable sperm for later ICSI attempts.

16. Embryo genetic testing when indicated. This may be discussed if both partners carry important CFTR variants. The purpose is to reduce the chance of transferring an embryo affected by a serious CFTR-related disorder. The mechanism is selection based on embryo genetics after IVF.

17. Donor sperm. This is a non-surgical option when the couple does not want surgery, IVF, or genetic risk. The purpose is pregnancy without passing on the male genetic condition. The mechanism is using screened donor sperm for assisted conception.

18. Adoption or child-free counseling. These are valid family-building pathways. The purpose is to give full, respectful choices. The mechanism is removal of pressure that every couple must use invasive fertility treatment.

19. Long-term follow-up for CFTR-related symptoms. Men with isolated CBAVD can rarely later show respiratory or pancreatic features. The purpose is early detection. The mechanism is periodic symptom review and referral if sinus, chest, or digestive symptoms appear.

20. Healthy lifestyle support. This does not cure CBAVD, but it may protect general sperm quality and procedure readiness. The purpose is better overall reproductive health. The mechanism is better sleep, normal weight, exercise, stopping smoking, and avoiding heat and toxins, which may protect the sperm that will later be retrieved.

Drug Treatments: What Is Proven and What Is Not

There are no FDA-approved drugs specifically for isolated CBAVD itself. The most evidence-based “medical” treatments are for associated cystic fibrosis in people with eligible CFTR mutations or for the female partner’s IVF cycle. I am not padding this section with invented medicines because that would be inaccurate.

Ivacaftor (Kalydeco). Drug class: CFTR potentiator. FDA dosing for many eligible patients is 150 mg by mouth every 12 hours with fat-containing food. Purpose: improve CFTR channel opening in selected mutations. Mechanism: helps defective CFTR protein work better at the cell surface. Side effects can include headache, upper respiratory symptoms, liver test elevation, and cataract warnings in children. This drug is not used to regrow the vas deferens, but it may help patients who have an eligible CFTR mutation and broader cystic-fibrosis disease.

Lumacaftor/ivacaftor (Orkambi). Drug class: CFTR corrector plus potentiator. Purpose: treat cystic fibrosis in eligible mutation groups. Mechanism: lumacaftor helps more CFTR protein reach the cell surface, and ivacaftor improves channel function. Important adverse effects include chest tightness, liver problems, drug interactions, and rare severe allergy warnings. It may matter only if the patient has broader CF disease, not isolated CBAVD alone.

Tezacaftor/ivacaftor (Symdeko). Drug class: CFTR corrector plus potentiator. Purpose: treat eligible cystic fibrosis genotypes. Mechanism: improves processing and function of CFTR protein. Side effects include headache, nausea, sinus symptoms, liver concerns, and more recent label safety updates. Again, this is not a tube-building drug for CBAVD; it is only relevant when CBAVD is part of CFTR-related disease with an eligible mutation.

Elexacaftor/tezacaftor/ivacaftor (Trikafta). Drug class: triple-combination CFTR modulator. Purpose: treat many people with cystic fibrosis who carry at least one F508del mutation or another approved responsive mutation. Mechanism: two correctors plus one potentiator improve CFTR protein quantity and function. Side effects include rash, liver injury risk, drug interactions, and recent FDA safety-label updates. It does not reverse congenital absence of the vas deferens, but it can be highly important for eligible patients with systemic CF disease.

Vanzacaftor/tezacaftor/deutivacaftor (Alyftrek). Drug class: next-generation CFTR triple combination. Purpose: treatment of eligible cystic fibrosis patients, not isolated CBAVD. Mechanism: improves defective CFTR protein processing and channel activity. Side effects and dose details follow the FDA label. This may become relevant only in a patient whose infertility diagnosis is part of a wider CFTR disease picture.

Follitropin beta, ganirelix, hCG, and progesterone. These drugs are often used in IVF cycles for the female partner, not to treat the missing vas in the male. Their purpose is egg stimulation, prevention of premature ovulation, final egg maturation, and embryo support. Their mechanism is control of the ovarian cycle so retrieved male sperm can be used with ICSI. They are part of the couple’s fertility pathway, not a cure for CBAVD.

Dietary Molecular Supplements

No supplement is proven to fix CBAVD, and major male infertility guidelines say the benefit of supplements is questionable and evidence is not strong enough to recommend specific agents for all men. Still, some clinics discuss zinc, selenium, coenzyme Q10, L-carnitine, folate, vitamins C, D, and E, omega-3 fatty acids, and N-acetylcysteine as general antioxidant or sperm-support supplements. Their purpose is to support overall sperm health, not to rebuild the vas deferens. The proposed mechanism is reduction of oxidative stress and support of mitochondrial function, but this evidence comes from male infertility research in general, not from strong CBAVD-specific trials. Use should be individualized with a fertility specialist.

Immunity Booster, Regenerative, and Stem Cell Drugs

At present, there are no approved immunity-booster drugs, regenerative drugs, or stem-cell drugs that are established treatments for CBAVD. Gene therapy and improved CFTR-restoring treatments are active areas of research in cystic fibrosis, but they are not standard approved therapy for isolated congenital absence of the vas deferens. This means clinics should not sell “stem cell cure” promises for CBAVD without strong evidence.

Surgeries or Procedures and Why They Are Done

The most important procedures are PESA, MESA, TESE, IVF, and ICSI. PESA and MESA are done to collect sperm from the epididymis. TESE is done to collect sperm directly from the testis when needed. IVF is done to handle eggs outside the body, and ICSI is done because one retrieved sperm can be injected directly into one egg. These procedures are done because the sperm pathway is absent, not because the testis usually fails to make sperm.

Prevention Points

CBAVD itself is congenital, so it usually cannot be prevented after birth. Prevention in this condition mostly means prevention of missed diagnosis, genetic surprises, and treatment delays. Helpful steps are: early infertility assessment, semen testing, careful physical exam, CFTR testing, partner carrier testing, genetic counseling, renal ultrasound, couple-based fertility planning, avoidance of unproven “cure” clinics, and early referral to a reproductive urologist and IVF team.

When to See Doctors

See a doctor if pregnancy has not happened after regular unprotected sex, if semen volume is very low, if a doctor cannot feel the vas deferens on exam, or if there is a family history of cystic fibrosis or unexplained male infertility. Also seek care if there are chronic sinus, chest, digestive, or pancreatic symptoms, because CBAVD can be part of a broader CFTR-related condition.

What to Eat and What to Avoid

There is no special diet that cures CBAVD. A practical plan is to eat enough protein, vegetables, fruits, beans, nuts, whole grains, fish, and healthy fats; maintain a healthy weight; stay hydrated; and avoid smoking, heavy alcohol, anabolic steroids, overheated testicular exposure, and environmental toxins. If the patient also has cystic-fibrosis-related digestive disease, diet should be tailored by a specialist. Supplements should not replace medical fertility treatment.

FAQs

Can a man with CBAVD have sex normally? Yes. Libido, erections, and orgasm are usually normal.

Can he father a biological child? Often yes, through sperm retrieval and IVF/ICSI.

Does semen always look abnormal? Not always by appearance, but volume is often low and sperm are absent.

Is CBAVD the same as cystic fibrosis? No, but it is strongly related to CFTR mutations and can be a CFTR-related disorder.

Can drugs reopen the tubes? No proven drug can do that.

Should the partner be tested? Usually yes, for CFTR carrier status.

Are kidneys ever involved? Yes, urinary tract abnormalities can occur, so ultrasound is recommended.

Is testosterone low? Usually not. CBAVD is usually an obstruction problem, not a testosterone problem.

Do supplements cure it? No. At best they may support general sperm health, and evidence is limited.

Is surgery always needed? Surgery or a sperm retrieval procedure is usually needed for biological fatherhood.

Can the condition be found on physical exam? Often yes, because both vas deferens may be absent on palpation.

Is natural pregnancy possible? Usually not, because sperm cannot reach the semen.

Can children inherit related problems? Yes, especially if both parents carry important CFTR variants.

Is it dangerous to general health? The infertility itself is usually the main issue, but some men may later show mild CFTR-related respiratory or pancreatic disease.

Who should manage this condition? A reproductive urologist, fertility specialist, and genetic counselor are the best team.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: March 10, 2025.